Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy

Seungyong Shin; Pyunghwajun Lee; Jieun Han; Se-Na Kim; Jaesung Lim; Dae-Hwan Park; Taejong Paik; Junhong Min; Chun Gwon Park; Wooram Park

doi:10.1007/s13770-022-00515-8

Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy

Tissue Eng Regen Med. 2023 Jun;20(3):371-387. doi: 10.1007/s13770-022-00515-8. Epub 2023 Mar 3.

Authors

Seungyong Shin^#¹, Pyunghwajun Lee^#², Jieun Han^{1

3}, Se-Na Kim⁴, Jaesung Lim^{2

5}, Dae-Hwan Park⁶, Taejong Paik⁷, Junhong Min⁸, Chun Gwon Park^{9

10

11}, Wooram Park^{12

13}

Affiliations

¹ Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea.
² Department of Global Biomedical Engineering, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea.
³ Institute of Biotechnology and Bioengineering, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea.
⁴ Institute of Medical and Biological Engineering, Medical Research Center, Seoul National University, Seoul, 03080, Republic of Korea.
⁵ Department of Intelligent Precision Healthcare Convergence, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea.
⁶ Department of Engineering Chemistry, Chungbuk National University, Cheongju, Chungbuk, 28644, Republic of Korea.
⁷ School of Integrative Engineering, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul, 06974, Republic of Korea.
⁸ School of Integrative Engineering, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul, 06974, Republic of Korea. junmin@cau.ac.kr.
⁹ Department of Global Biomedical Engineering, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea. chunpark@skku.edu.
¹⁰ Department of Intelligent Precision Healthcare Convergence, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea. chunpark@skku.edu.
¹¹ Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea. chunpark@skku.edu.
¹² Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea. parkwr@skku.edu.
¹³ Institute of Biotechnology and Bioengineering, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea. parkwr@skku.edu.

^# Contributed equally.

Abstract

Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) has emerged as an innovative immunotherapy for hematological cancer treatment. However, the limited effect on solid tumors, complex processes, and excessive manufacturing costs remain as limitations of CAR-T therapy. Nanotechnology provides an alternative to the conventional CAR-T therapy. Owing to their unique physicochemical properties, nanoparticles can not only serve as a delivery platform for drugs but also target specific cells. Nanoparticle-based CAR therapy can be applied not only to T cells but also to CAR-natural killer and CAR-macrophage, compensating for some of their limitations. This review focuses on the introduction of nanoparticle-based advanced CAR immune cell therapy and future perspectives on immune cell reprogramming.

Keywords: Cancer immunotherapy; Chimeric antigen receptor (CAR); Genetic engineering; Immune cell reprograming; Nanoparticle.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Immunotherapy
Immunotherapy, Adoptive
Nanoparticles*
Neoplasms* / therapy
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen*

Substances

Receptors, Chimeric Antigen
Receptors, Antigen, T-Cell